Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma
This study aimed to compare the real-life results of TECAM, a thiotepa-based conditioning regimen consisting of thiotepa (40 mg/m2 days - 5 to - 2), etoposide (200 mg/m2 days - 6 to - 3), cytarabine (200 mg/m2 days - 4 to - 1), cyclophosphamide (60 mg/kg day - 3), and melphalan (60 mg/m2 days - 2 to - 1) with that of the conventional carmustine-based regimen BEAM. We reviewed 125 consecutive patients who underwent a first autologous transplantation (ASCT) for B-cell lymphomas at a large tertiary transplantation center between 1999 and 2014. TECAM (n = 65) and BEAM (n = 60) had comparable results (3yPFS 49 vs 62%, P = 0.16; 3yOS 64 vs 71%, P = 0.44; TRM 1.6 vs 5%, P = 0.35) without a difference in toxicity or time to engraftment. Notably, comparable outcomes were observed even though patients treated with TECAM were older (55 vs 44) and had a trend towards more prior lines of therapy (> 2 prior lines: 43 vs 27%, P = 0.08). In this regard, 23% of TECAM patients were over the age of 65 yet could withstand therapy with similar results to younger patients. We conclude that, replacing carmustine by thiotepa and cyclophosphamide for ASCT conditioning, has comparable efficacy and safety profiles with a possible advantage in older patients.